Organization | Israel Defense Force

Israel Defense Force Report issue

Government Phase 3 Phase 4

Founded: HaKirya Israel (1948)

Organization Overview

First Clinical Trial

2002

NCT00237016

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Head of Motion Sickness and Human Performance Laboratory, Principal Investigator | Medical Corps, Israel Defense Force

Active Ingredients

Drugs in Phase 4 Trials (2)

lindane (kwell) (1 trial)

meclizine (antivert) (2 trials)

Drugs in Phase 3 Trials (3)

doxycycline (vibramycin) (2 trials)

ketamine (ketalar) (1 trial)

morphine (1 trial)

Drugs in Other Trials (3)

cinnarizine (Stugeron) (1 trial)

rivastigmine (exelon) (1 trial)

scopolamine (transderm scop) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Pain (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Fever (Phase 3)

Motion Sickness (Phase 4)

Relapsing Fever (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 8